Kura Oncology and Kyowa Kirin have shared details of the phase 2 win for their oral leukemia treatment ziftomenib as the FDA ...

Several analysts are hailing Merus as the sure winner in the race to a new treatment for head and neck squamous cell ...

Ernexa Therapeutics’ “Trojan Horse” stem cells can infiltrate ovarian tumors in mice, boosting T cell activity and leading to ...

The Trump administration's proposed funding cuts to the National Institutes of Health (NIH), including the National Cancer ...

The clinical trial tech companies Medidata and Medable are both taking to the floor of the American Society of Clinical ...

The founder of 23andMe, Anne Wojcicki, has asked a federal bankruptcy court judge to reopen an auction for the genetic ...

Sanofi paid $55 million to partner with the biotech in 2019 and handed over a further $22 million to expand the collaboration ...

The first half of this year has been riddled with market volatility and geopolitical tension. But 2025’s American Society of ...

Bristol Myers Squibb is paying BioNTech $3.5 billion to board the PD-1/L1xVEGF-A bandwagon. The deal, which features up to $7 ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

| When clinical trial steps are managed separately, the study suffers from compounded delays. Discover proven solutions from ...

Be successful developing Internet of Healthcare Things with realtime medical device data integration. Learn more.